Literature DB >> 32576077

Combination of pregabalin and transcutaneous electrical nerve stimulation for neuropathic pain in a stroke patient after contralateral C7 nerve transfer: a case report.

Peng Xia1, Ting Yang1, Xiaoju Wang1, Xueping Li1.   

Abstract

BACKGROUND: Contralateral C7 nerve transfer is a new surgical treatment for stroke patients with unilateral upper extremity paralysis, but neuropathic pain in the nonparalyzed side is the common complication after surgery. We report a stroke patient with neuropathic pain after C7 nerve transfer who received combination treatment of transcutaneous electrical nerve stimulation(TENS) and pregabalin. CASE
SUMMARY: A 53-year old, 6 months post-stroke patient with right hemiplegia after contralateral C7 nerve transfer was admitted in our department with a significant neuropathic pain in his left upper extremity. The treatment of pregabalin and TENS were used for patient. The visual analogue scale(VAS), medical outcomes study sleep scale(MOS-SS) and hospital anxiety and depression scale(HADS) were assessed after 1 months treatment. After treatment, the pain of his nonparalyzed upper extremity was relieved, the sleeping quality and the anxiety and depression were improved in patient.
CONCLUSION: This report suggests that the combination of pregabalin and TENS have prominent clinical effects on neuropathic pain of nonparalyzed side in stroke patients after contralateral C7 nerve transfer.

Entities:  

Keywords:  Contralateral C7 nerve transfer; TENS; neuropathic pain; pregabalin

Mesh:

Substances:

Year:  2020        PMID: 32576077     DOI: 10.1080/00207454.2020.1786687

Source DB:  PubMed          Journal:  Int J Neurosci        ISSN: 0020-7454            Impact factor:   2.292


  1 in total

1.  Intervention Effect of Rehabilitation Robotic Bed Under Machine Learning Combined With Intensive Motor Training on Stroke Patients With Hemiplegia.

Authors:  Guangliang Liu; Haiqin Cai; Naruemon Leelayuwat
Journal:  Front Neurorobot       Date:  2022-06-09       Impact factor: 3.493

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.